Alpha1-Antitrypsin Deficiency Clinical Trials

19 clinical trials for Alpha1-Antitrypsin Deficiency across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems — RECRUITING
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein — RECRUITING · PHASE3
• Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) — RECRUITING · PHASE3
• Preparation of IPSC for Cell Gene Editing for the Treatment of AATD — RECRUITING · NA
• Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) — NOT_YET_RECRUITING · PHASE4
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency — COMPLETED · PHASE1
• An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema — WITHDRAWN · PHASE4
• Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype — COMPLETED · PHASE2
• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) — COMPLETED · PHASE1
• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency — COMPLETED · PHASE1
• GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study — COMPLETED · PHASE3
• Aralast alpha1-proteinase Inhibitor Surveillance Study — TERMINATED · PHASE4
• GLASSIA Infusion Rate Study — COMPLETED · PHASE4
• Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency — TERMINATED · PHASE3
• Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency — COMPLETED · PHASE1
• Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency — COMPLETED · PHASE1
• ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study — WITHDRAWN · PHASE4
• Liver Disease in Patients With alpha1-antitrypsin Deficiency — OTHER

Refine this search